ARTICLE | Clinical News
Sulodexide: Interim Phase II data
May 9, 2005 7:00 AM UTC
Interim data from a double-blind, placebo-controlled Phase II trial in 120 evaluable patients showed that 24% of patients receiving 200 or 400 mg of KRX-101 showed therapeutic success vs. 13% with pla...